No Widgets found in the Sidebar

Aclaris Therapeutics Shares Slide to Two-Year Lows on Study Failure >ACRS

  ​The Wayne, Pa., company, which is also studying zunsemetinib in rheumatoid arthritis and psoriatic arthritis, said the drug was generally well ...  The Wayne, Pa., company, which is also studying…

Read More

Why The Aclaris Therapeutics Stock Increased 8.67% (ACRS)

  ​Rheumatoid Arthritis (ATI-450-RA-202): This Phase 2b dose-ranging trial to investigate the efficacy, safety, tolerability, pharmacokinetics (PK) ...  Rheumatoid Arthritis (ATI-450-RA-202): This Phase 2b dose-ranging trial to investigate the efficacy, safety,…

Read More

Aclaris Therapeutics Provides 2023 Outlook – StreetInsider.com

  ​Rheumatoid Arthritis (ATI-450-RA-202): This Phase 2b dose ranging trial to investigate the efficacy, safety, tolerability, pharmacokinetics (PK) ...  Rheumatoid Arthritis (ATI-450-RA-202): This Phase 2b dose ranging trial to investigate the…

Read More